Clinical Trial Update: SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating SHR-A1811 in combination with Pyrotinib for locally advanced or metastatic HER2-positive breast cancer; trial status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)
• SHR-A1811

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Metastatic Breast Cancer With HER2 Positive | Phase 2 | Status: NOT_YET_RECRUITING